Medtronic Financial Statements (MDT) |
||||||||||
Medtronicsmart-lab.ru | % | 2022 | 2023 | 2023 | 2024 | 2024 | LTM ? | |||
---|---|---|---|---|---|---|---|---|---|---|
Report date | 23.06.2022 | 30.04.2023 | 22.06.2023 | 30.04.2024 | 20.06.2024 | 19.11.2024 | ||||
Currency | USD | USD | USD | USD | USD | USD | ||||
Financial report URL | ||||||||||
Revenue, bln rub | ? | 31 686 | 31 227 | 31 227 | 32 364 | 32 822 | ||||
Operating Income, bln rub | 5 752 | 5 485 | 5 485 | 5 144 | 4 211 | |||||
EBITDA, bln rub | ? | 9 554 | 9 042 | 8 475 | 9 056 | 6 614 | ||||
Net profit, bln rub | ? | 5 039 | 3 758 | 3 758 | 3 676 | 4 009 | ||||
OCF, bln rub | ? | 7 346 | 6 039 | 6 039 | 6 787 | 5 707 | ||||
CAPEX, bln rub | ? | 1 368 | 1 459 | 1 459 | 1 587 | 1 870 | ||||
FCF, bln rub | ? | 5 978 | 4 580 | 4 580 | 5 200 | 3 837 | ||||
Dividend payout, bln rub | 3 383 | 3 616 | 3 616 | 3 666 | 3 606 | |||||
Ordinary share dividend yield, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0 | ||||
Dividend payout ratio, % | 67.1% | 96.2% | 96.2% | 99.7% | 89.9% | |||||
OPEX, bln rub | 15 633 | 14 678 | 14 678 | 16 129 | 14 328 | |||||
Cost of production, bln rub | 10 145 | 10 719 | 10 719 | 12 911 | 12 697 | |||||
R&D, bln rub | 2 746 | 2 696 | 2 696 | 2 735 | 2 724 | |||||
Interest expenses, bln rub | 553.0 | 636.0 | 636.0 | 719.0 | 745.0 | |||||
Assets, bln rub | 90 981 | 90 948 | 90 948 | 89 981 | 89 981 | 90 042 | ||||
Net Assets, bln rub | ? | 52 551 | 51 483 | 51 483 | 50 214 | 50 214 | 48 494 | |||
Debt, bln rub | 24 114 | 24 364 | 24 364 | 25 024 | 26 047 | 28 326 | ||||
Cash, bln rub | 10 573 | 7 959 | 7 959 | 8 005 | 8 005 | 1 394 | ||||
Net debt, bln rub | 13 541 | 16 405 | 16 405 | 17 019 | 18 042 | 26 932 | ||||
Ordinary share price, rub | 104.4 | 91.0 | 91.0 | 80.2 | 79.7 | 72.0 | ||||
Number of ordinary shares, mln | 1 342 | 1 330 | 1 330 | 1 328 | 1 282 | |||||
Market cap, bln rub | 140 093 | 120 945 | 120 945 | 0 | 105 871 | 92 333 | ||||
EV, bln rub | ? | 153 634 | 137 350 | 137 350 | 17 019 | 123 913 | 119 265 | |||
Book value, bln rub | -3 546 | -4 786 | -4 786 | 9 228 | -3 997 | -5 090 | ||||
EPS, rub | ? | 3.75 | 2.83 | 2.83 | 2.77 | 3.13 | ||||
FCF/share, rub | 4.45 | 3.44 | 3.44 | 3.92 | 2.99 | |||||
BV/share, rub | -2.64 | -3.60 | -3.60 | -3.01 | -3.97 | |||||
EBITDA margin, % | ? | 30.2% | 29.0% | 27.1% | 28.0% | 20.2% | ||||
Net margin, % | ? | 15.9% | 12.0% | 12.0% | 11.4% | 12.2% | ||||
FCF yield, % | ? | 4.27% | 3.79% | 3.79% | 0.00% | 4.91% | 4.16% | |||
ROE, % | ? | 9.59% | 7.30% | 7.30% | 0.00% | 7.32% | 8.27% | |||
ROA, % | ? | 5.54% | 4.13% | 4.13% | 0.00% | 4.09% | 4.45% | |||
P/E | ? | 27.8 | 32.2 | 32.2 | 28.8 | 23.0 | ||||
P/FCF | 23.4 | 26.4 | 26.4 | 20.4 | 24.1 | |||||
P/S | ? | 4.42 | 3.87 | 3.87 | 3.27 | 2.81 | ||||
P/BV | ? | -39.5 | -25.3 | -25.3 | 0.00 | -26.5 | -18.1 | |||
EV/EBITDA | ? | 16.1 | 15.2 | 16.2 | 13.7 | 18.0 | ||||
Debt/EBITDA | 1.42 | 1.81 | 1.94 | 1.99 | 4.07 | |||||
R&D/CAPEX, % | 200.7% | 184.8% | 184.8% | 172.3% | 145.7% | |||||
CAPEX/Revenue, % | 4.32% | 4.67% | 4.67% | 4.90% | 5.70% | |||||
Medtronic shareholders |